We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Biomimetic drugs

News List

EU regulators to review Sandoz’ Neulasta biosimilar pharmatimes
October 31, 2017
The European Medicines Agency has accepted for review Novartis unit Sandoz’ biosimilar of Amgen’s Neulasta.
Mylan and Biocon Neulasta biosimilar knocked back by FDA pharmafile
October 12, 2017
Mylan and Biocon’s biosimilar version of Amgen’s blockbuster, Neulasta (pegfilgrastim), will have to wait a bit longer before getting the nod from the FDA, after receiving a CRL related manufacturing plant issues
Risky endeavours for biosimilars market europeanpharmaceuticalreview
August 10, 2017
Bringing a biosimilar from early development to market is a risky endeavour say Magnus Franzen (left) and Chris Isler, biosimilar experts at PA Consulting Group…